Search results
Showing 2011 to 2025 of 2172 results for technology appraisal
Discontinued Reference number: GID-TA11207
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued Reference number: GID-TA11209
Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]
Discontinued Reference number: GID-TA11210
In development Reference number: GID-TA11689 Expected publication date: TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]
Discontinued Reference number: GID-TA11238
In development Reference number: GID-TA11546 Expected publication date: TBC
In development Reference number: GID-TA11345 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
In development Reference number: GID-TA11104 Expected publication date: TBC
In development Reference number: GID-TA11679 Expected publication date: TBC
psoriatic arthritis, which have led to positive recommendations in NICE technology appraisals, no such good-quality...
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
In development Reference number: GID-TA11310 Expected publication date: TBC
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.